NCT04578600 2025-04-24CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell LymphomaUniversity of California, DavisPhase 1 Completed8 enrolled
NCT04722601 2024-05-16A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular LymphomaUniversity of ChicagoPhase 1/2 Terminated2 enrolled 7 charts